Table 2.
Nerve score characteristics
| Group | Results | P | |||
|---|---|---|---|---|---|
| Control (n = 30) | Low‐risk (n = 22) | High‐risk (n = 43) | ALL/HL/HC/LC | Paratumor vs. tumor | |
| Paratumor, TH | 0.000 | 0.000Hth | |||
| 0 (%) | 14 (46.7) | 5 (22.7) | 3 (7.0) | 0.001HL | — |
| 1 (%) | 13 (43.3) | 10 (45.5) | 5 (11.6) | 0.000HC | |
| 2 (%) | 2 (6.7) | 3 (13.6) | 17 (39.5) | 0.026LC | |
| 3 (%) | 1 (3.3) | 4 (18.2) | 13 (30.2) | ||
| 4 (%) | 0 (0) | 0 (0) | 5 (11.6) | ||
| Tumor, TH | 0.160 | 0.034Lth | |||
| 0 (%) | 14 (46.7) | 10 (45.5) | 10 (23.3) | 0.125HL | — |
| 1 (%) | 13 (43.3) | 10 (45.5) | 29 (67.4) | 0.094HC | |
| 2 (%) | 2 (6.7) | 2 (9.1) | 4 (9.3) | 0.984LC | |
| 3 (%) | 1 (3.3) | 0 (0) | 0 (0) | ||
| 4 (%) | 0 (0) | 0 (0) | 0 (0) | ||
| Paratumor, VAChT | 0.171 | 0.000Hvt | |||
| 0 (%) | 15 (50.0) | 12 (54.5) | 15 (34.9) | 0.109HL | — |
| 1 (%) | 14 (46.7) | 9 (40.9) | 23 (53.5) | 0.137HC | |
| 2 (%) | 0 (0) | 1 (4.5) | 5 (11.6) | 0.784LC | |
| 3 (%) | 1 (3.3) | 0 (0) | 0 (0) | ||
| 4 (%) | 0 (0) | 0 (0) | 0 (0) | ||
| Tumor, VAChT | 0.000 | 0.034Lvt | |||
| 0 (%) | 15 (50.0) | 7 (31.8) | 2 (4.7) | 0.001HL | — |
| 1 (%) | 14 (46.7) | 8 (36.4) | 10 (23.3) | 0.000HC | |
| 2 (%) | 0 (0) | 4 (18.2) | 17 (39.5) | 0.038LC | |
| 3 (%) | 1 (3.3) | 3 (13.6) | 11 (25.6) | ||
| 4 (%) | 0 (0) | 0 (0) | 3 (7.0) | ||
HC, high‐risk compared with the control group; HL, high‐risk compared with the low‐risk group; Hth/Lth, mean tyrosine hydroxylase (TH) nerve score in the paratumoral area compared with that in the tumor in the high/low risk group, respectively; Hvt/Lvt, mean vesicular acetylcholine transporter (VAChT) nerve score in the tumor compared with that in the paratumoral area in the high/low risk group, respectively; LC, low‐risk compared with the control group.